Study: NCT01171313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP21279 and carbidopa (experimental)
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed XP21279 and Carbidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP21279 and carbidopa (experimental)
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed XP21279 and Carbidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP21279 and carbidopa (experimental)
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed XP21279 and Carbidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet (comparator)
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed Sinemet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet (comparator)
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed Sinemet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet (comparator)
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed Sinemet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet (comparator)
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed Sinemet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for XP21279 and carbidopa
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for XP21279 and carbidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for XP21279 and carbidopa
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for XP21279 and carbidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for XP21279 and carbidopa
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for XP21279 and carbidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for XP21279 and carbidopa
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for XP21279 and carbidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Sinemet
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for Sinemet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Sinemet
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for Sinemet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Sinemet
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for Sinemet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Sinemet
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for Sinemet